The parasitic worm product ES-62 targets myeloid differentiation factor 88-dependent effector mechanisms to suppress antinuclear antibody production and proteinuria in MRL/lpr mice

David T. Rodgers, Mairi A. McGrath, Miguel A. Pineda, Lamyaa Al-Riyami, Justyna Rzepecka, Felicity Lumb, William Harnett, Margaret M. Harnett

Research output: Contribution to journalArticle

25 Citations (Scopus)
198 Downloads (Pure)

Abstract

Objective The hygiene hypothesis suggests that parasitic helminths (worms) protect against the development of autoimmune disease via a serendipitous side effect of worm-derived immunomodulators that concomitantly promote parasite survival and limit host pathology. The aim of this study was to investigate whether ES-62, a phosphorylcholine-containing glycoprotein secreted by the filarial nematode Acanthocheilonema viteae, protects against kidney damage in an MRL/lpr mouse model of systemic lupus erythematosus (SLE). Methods MRL/lpr mice progressively produce high levels of autoantibodies, and the resultant deposition of immune complexes drives kidney pathology. The effects of ES-62 on disease progression were assessed by measurement of proteinuria, assessment of kidney histology, determination of antinuclear antibody (ANA) production and cytokine levels, and flow cytometric analysis of relevant cellular populations. Results ES-62 restored the disrupted balance between effector and regulatory B cells in MRL/lpr mice by inhibiting plasmablast differentiation, with a consequent reduction in ANA production and deposition of immune complexes and C3a in the kidneys. Moreover, by reducing interleukin-22 production, ES-62 may desensitize downstream effector mechanisms in the pathogenesis of kidney disease. Highlighting the therapeutic importance of resetting B cell responses, adoptive transfer of purified splenic B cells from ES-62-treated MRL/lpr mice mimicked the protection afforded by the helminth product. Mechanistically, this reflects down-regulation of myeloid differentiation factor 88 expression by B cells and also kidney cells, resulting in inhibition of pathogenic cross-talk among Toll-like receptor-, C3a-, and immune complex-mediated effector mechanisms. Conclusion This study provides the first demonstration of protection against kidney pathology by a parasitic worm-derived immunomodulator in a model of SLE and suggests therapeutic potential for drugs based on the mechanism of action of ES-62.
Original languageEnglish
Pages (from-to)1023-1035
Number of pages13
JournalArthritis and Rheumatology
Volume67
Issue number4
DOIs
Publication statusPublished - 27 Mar 2015

Fingerprint

Myeloid Differentiation Factor 88
Inbred MRL lpr Mouse
Helminths
Antinuclear Antibodies
Proteinuria
Antibody Formation
Pathology
Antigen-Antibody Complex
Cells
Kidney
Immunologic Factors
B-Lymphocytes
Systemic Lupus Erythematosus
Histology
Phosphorylcholine
Toll-Like Receptors
Acanthocheilonema
Regulatory B-Lymphocytes
Hygiene Hypothesis
Autoantibodies

Keywords

  • parasitic helminths
  • immunomodulator
  • glycoprotein
  • Acanthocheilonema viteae
  • kidney damage

Cite this

Rodgers, David T. ; McGrath, Mairi A. ; Pineda, Miguel A. ; Al-Riyami, Lamyaa ; Rzepecka, Justyna ; Lumb, Felicity ; Harnett, William ; Harnett, Margaret M. / The parasitic worm product ES-62 targets myeloid differentiation factor 88-dependent effector mechanisms to suppress antinuclear antibody production and proteinuria in MRL/lpr mice. In: Arthritis and Rheumatology. 2015 ; Vol. 67, No. 4. pp. 1023-1035.
@article{448b86f4aa2446489ffd8d321ad1e611,
title = "The parasitic worm product ES-62 targets myeloid differentiation factor 88-dependent effector mechanisms to suppress antinuclear antibody production and proteinuria in MRL/lpr mice",
abstract = "Objective The hygiene hypothesis suggests that parasitic helminths (worms) protect against the development of autoimmune disease via a serendipitous side effect of worm-derived immunomodulators that concomitantly promote parasite survival and limit host pathology. The aim of this study was to investigate whether ES-62, a phosphorylcholine-containing glycoprotein secreted by the filarial nematode Acanthocheilonema viteae, protects against kidney damage in an MRL/lpr mouse model of systemic lupus erythematosus (SLE). Methods MRL/lpr mice progressively produce high levels of autoantibodies, and the resultant deposition of immune complexes drives kidney pathology. The effects of ES-62 on disease progression were assessed by measurement of proteinuria, assessment of kidney histology, determination of antinuclear antibody (ANA) production and cytokine levels, and flow cytometric analysis of relevant cellular populations. Results ES-62 restored the disrupted balance between effector and regulatory B cells in MRL/lpr mice by inhibiting plasmablast differentiation, with a consequent reduction in ANA production and deposition of immune complexes and C3a in the kidneys. Moreover, by reducing interleukin-22 production, ES-62 may desensitize downstream effector mechanisms in the pathogenesis of kidney disease. Highlighting the therapeutic importance of resetting B cell responses, adoptive transfer of purified splenic B cells from ES-62-treated MRL/lpr mice mimicked the protection afforded by the helminth product. Mechanistically, this reflects down-regulation of myeloid differentiation factor 88 expression by B cells and also kidney cells, resulting in inhibition of pathogenic cross-talk among Toll-like receptor-, C3a-, and immune complex-mediated effector mechanisms. Conclusion This study provides the first demonstration of protection against kidney pathology by a parasitic worm-derived immunomodulator in a model of SLE and suggests therapeutic potential for drugs based on the mechanism of action of ES-62.",
keywords = "parasitic helminths , immunomodulator, glycoprotein , Acanthocheilonema viteae , kidney damage",
author = "Rodgers, {David T.} and McGrath, {Mairi A.} and Pineda, {Miguel A.} and Lamyaa Al-Riyami and Justyna Rzepecka and Felicity Lumb and William Harnett and Harnett, {Margaret M.}",
year = "2015",
month = "3",
day = "27",
doi = "10.1002/art.39004",
language = "English",
volume = "67",
pages = "1023--1035",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
number = "4",

}

The parasitic worm product ES-62 targets myeloid differentiation factor 88-dependent effector mechanisms to suppress antinuclear antibody production and proteinuria in MRL/lpr mice. / Rodgers, David T.; McGrath, Mairi A.; Pineda, Miguel A.; Al-Riyami, Lamyaa; Rzepecka, Justyna; Lumb, Felicity; Harnett, William; Harnett, Margaret M.

In: Arthritis and Rheumatology, Vol. 67, No. 4, 27.03.2015, p. 1023-1035.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The parasitic worm product ES-62 targets myeloid differentiation factor 88-dependent effector mechanisms to suppress antinuclear antibody production and proteinuria in MRL/lpr mice

AU - Rodgers, David T.

AU - McGrath, Mairi A.

AU - Pineda, Miguel A.

AU - Al-Riyami, Lamyaa

AU - Rzepecka, Justyna

AU - Lumb, Felicity

AU - Harnett, William

AU - Harnett, Margaret M.

PY - 2015/3/27

Y1 - 2015/3/27

N2 - Objective The hygiene hypothesis suggests that parasitic helminths (worms) protect against the development of autoimmune disease via a serendipitous side effect of worm-derived immunomodulators that concomitantly promote parasite survival and limit host pathology. The aim of this study was to investigate whether ES-62, a phosphorylcholine-containing glycoprotein secreted by the filarial nematode Acanthocheilonema viteae, protects against kidney damage in an MRL/lpr mouse model of systemic lupus erythematosus (SLE). Methods MRL/lpr mice progressively produce high levels of autoantibodies, and the resultant deposition of immune complexes drives kidney pathology. The effects of ES-62 on disease progression were assessed by measurement of proteinuria, assessment of kidney histology, determination of antinuclear antibody (ANA) production and cytokine levels, and flow cytometric analysis of relevant cellular populations. Results ES-62 restored the disrupted balance between effector and regulatory B cells in MRL/lpr mice by inhibiting plasmablast differentiation, with a consequent reduction in ANA production and deposition of immune complexes and C3a in the kidneys. Moreover, by reducing interleukin-22 production, ES-62 may desensitize downstream effector mechanisms in the pathogenesis of kidney disease. Highlighting the therapeutic importance of resetting B cell responses, adoptive transfer of purified splenic B cells from ES-62-treated MRL/lpr mice mimicked the protection afforded by the helminth product. Mechanistically, this reflects down-regulation of myeloid differentiation factor 88 expression by B cells and also kidney cells, resulting in inhibition of pathogenic cross-talk among Toll-like receptor-, C3a-, and immune complex-mediated effector mechanisms. Conclusion This study provides the first demonstration of protection against kidney pathology by a parasitic worm-derived immunomodulator in a model of SLE and suggests therapeutic potential for drugs based on the mechanism of action of ES-62.

AB - Objective The hygiene hypothesis suggests that parasitic helminths (worms) protect against the development of autoimmune disease via a serendipitous side effect of worm-derived immunomodulators that concomitantly promote parasite survival and limit host pathology. The aim of this study was to investigate whether ES-62, a phosphorylcholine-containing glycoprotein secreted by the filarial nematode Acanthocheilonema viteae, protects against kidney damage in an MRL/lpr mouse model of systemic lupus erythematosus (SLE). Methods MRL/lpr mice progressively produce high levels of autoantibodies, and the resultant deposition of immune complexes drives kidney pathology. The effects of ES-62 on disease progression were assessed by measurement of proteinuria, assessment of kidney histology, determination of antinuclear antibody (ANA) production and cytokine levels, and flow cytometric analysis of relevant cellular populations. Results ES-62 restored the disrupted balance between effector and regulatory B cells in MRL/lpr mice by inhibiting plasmablast differentiation, with a consequent reduction in ANA production and deposition of immune complexes and C3a in the kidneys. Moreover, by reducing interleukin-22 production, ES-62 may desensitize downstream effector mechanisms in the pathogenesis of kidney disease. Highlighting the therapeutic importance of resetting B cell responses, adoptive transfer of purified splenic B cells from ES-62-treated MRL/lpr mice mimicked the protection afforded by the helminth product. Mechanistically, this reflects down-regulation of myeloid differentiation factor 88 expression by B cells and also kidney cells, resulting in inhibition of pathogenic cross-talk among Toll-like receptor-, C3a-, and immune complex-mediated effector mechanisms. Conclusion This study provides the first demonstration of protection against kidney pathology by a parasitic worm-derived immunomodulator in a model of SLE and suggests therapeutic potential for drugs based on the mechanism of action of ES-62.

KW - parasitic helminths

KW - immunomodulator

KW - glycoprotein

KW - Acanthocheilonema viteae

KW - kidney damage

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84925797557&partnerID=40&md5=69524d68cd13cae3328dd783cebbd39d

UR - http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%292326-5205

U2 - 10.1002/art.39004

DO - 10.1002/art.39004

M3 - Article

VL - 67

SP - 1023

EP - 1035

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 4

ER -